These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25330015)

  • 21. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
    Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
    Romei C; Ciampi R; Elisei R
    Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of RET genetic variants in MEN2-associated pheochromocytoma.
    Siqueira DR; Ceolin L; Ferreira CV; Romitti M; Maia SC; Maciel LM; Maia AL
    Eur J Endocrinol; 2014 Jun; 170(6):821-8. PubMed ID: 24616415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism.
    Rotondi M; Ercolino T; Fonte R; Lagonigro MS; Leporati P; Villani L; La Manna L; Mannelli M; Chiovato L
    J Endocrinol Invest; 2009 Feb; 32(2):115-8. PubMed ID: 19411807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genetic polymorphisms: implications in the pathogenesis of medullary thyroid carcinoma].
    Rocha AP; Magalhães PK; Maia AL; Maciel LM
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):723-30. PubMed ID: 17891235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.
    Ceolin L; Romitti M; Siqueira DR; Vaz Ferreira C; Oliboni Scapineli J; Assis-Brazil B; Vieira Maximiano R; Dias Amarante T; de Souza Nunes MC; Weber G; Maia AL
    PLoS One; 2016; 11(2):e0147840. PubMed ID: 26829565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma.
    Penna-Martinez M; Ramos-Lopez E; Stern J; Kahles H; Hinsch N; Hansmann ML; Selkinski I; Grünwald F; Vorländer C; Bechstein WO; Zeuzem S; Holzer K; Badenhoop K
    Thyroid; 2012 Jul; 22(7):709-16. PubMed ID: 22690899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.
    Cebrian A; Lesueur F; Martin S; Leyland J; Ahmed S; Luccarini C; Smith PL; Luben R; Whittaker J; Pharoah PD; Dunning AM; Ponder BA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6268-74. PubMed ID: 16091499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
    Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
    Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
    Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.
    Neocleous V; Skordis N; Portides G; Efstathiou E; Costi C; Ioannou N; Pantzaris M; Anastasiadou V; Deltas C; Phylactou LA
    J Endocrinol Invest; 2011 Nov; 34(10):764-9. PubMed ID: 21422799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The RET oncogene in papillary thyroid carcinoma.
    Prescott JD; Zeiger MA
    Cancer; 2015 Jul; 121(13):2137-46. PubMed ID: 25731779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history.
    Halkova T; Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Sykorova P; Vlcek P; Reboun M; Katra R; Kodetova D; Schrumpf M; van Wezel T; Morreau H; Bendlova B
    Hum Pathol; 2015 Dec; 46(12):1962-9. PubMed ID: 26472164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma.
    Stephens LA; Powell NG; Grubb J; Jeremiah SJ; Bethel JA; Demidchik EP; Bogdanova TI; Tronko MD; Thomas GA
    Thyroid; 2005 Feb; 15(2):100-4. PubMed ID: 15753666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.